Progression of prodromal motor and non‐motor symptoms in the premotor phase study – 2‐year follow‐up data

Liepelt‐Scarfone, Inga; Brändle, Barbara; Yılmaz, Rezzak; Gauss, Katharina; Schaeffer, Eva; Timmers, Maarten; Wurster, Isabel; Brockmann, Kathrin; Maetzler, Walter; Nueten, Luc Van; Streffer, Johannes; Berg, Daniela

doi:10.1111/ene.13397

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study strengthens the notion of NMS antedating motor symptoms in PD by assessing the presence and time of onset of the full spectrum of pNMS using a validated NMS questionnaire (NMSQuest) in a population with recently diagnosed PD. Interpretation of previous studies evaluating the frequency and duration of onset of pNMS is limited by study methodological variability, lack of direct patient evaluation , long duration from PD diagnosis to study enrolment , utilization of non‐validated, custom‐made NMS questionnaires or studying only limited subsets of the spectrum on pNMS in PD cohorts or ‘at risk’ of PD cohorts .…”

Section: Discussionmentioning

confidence: 99%

Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease

Durcan

Wiblin

Lawson

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose The prevalence and duration of non‐motor symptoms (NMS) in prodromal Parkinson's disease (PD) has not been extensively studied. The aim of this study was to determine the prevalence and duration of prodromal NMS (pNMS) in a cohort of patients with recently diagnosed PD. Methods We evaluated the prevalence and duration of pNMS in patients with early PD ( n = 154). NMS were screened for using the Non‐Motor Symptom Questionnaire (NMSQuest). We subtracted the duration of the presence of each individual NMS reported from the duration of the earliest motor symptom. NMS whose duration preceded the duration of motor symptoms were considered a pNMS. Individual pNMS were then grouped into relevant pNMS clusters based on the NMSQuest domains. Motor subtypes were defined as tremor dominant, postural instability gait difficulty (PIGD) and indeterminate type according to the Movement Disorder Society Unified Parkinson's Disease Rating Scale revision. Results Prodromal NMS were experienced by 90.3% of patients with PD and the median number experienced was 4 (interquartile range, 2–7). A gender difference existed in the pNMS experienced, with males reporting more sexual dysfunction, forgetfulness and dream re‐enactment, whereas females reported more unexplained weight change and anxiety. There was a significant association between any prodromal gastrointestinal symptoms [odds ratio (OR), 2.30; 95% confidence interval (CI), 1.08–4.89, P = 0.03] and urinary symptoms (OR, 2.54; 95% CI, 1.19–5.35, P = 0.016) and the PIGD phenotype. Further analysis revealed that total pNMS were not significantly associated with the PIGD phenotype (OR, 1.10; 95% CI, 0.99–1.21, P = 0.068). Conclusions Prodromal NMS are common and a gender difference in pNMS experienced in prodromal PD may exist. The PIGD phenotype had a higher prevalence of prodromal gastrointestinal and urinary tract symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease

Durcan

Wiblin

Lawson

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…This result indirectly implies the slow evolution of NMSs. A study on progression markers in the premotor phase of PD showed that the frequency of nonmotor prodromal markers did not increase within 2 years, and that the progression of motor and nonmotor markers seemed independent 7 . Erro et al conducted a 2-year prospective clinical study of NMSs in patients with PD in Naples, Italy 8 .…”

Section: Introductionmentioning

confidence: 99%

The severity progression of non-motor symptoms in Parkinson’s disease: a 6-year longitudinal study in Taiwanese patients

Chen

Weng

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Nonmotor symptoms (NMSs) cause major burden in patients with Parkinson’s disease (PD). Previous NMSs progression studies mostly focused on the prevalence. We conducted a longitudinal study to identify the progression pattern by the severity. PD patients recruited from the outpatient clinics of a tertiary medical center were evaluated by the Unified Parkinson's Disease Rating Scale and Non-Motor Symptoms Scale (NMSS). A retrospective study with three-step analysis was performed. Step 1, the NMSs severity was compared among patients stratified by disease duration every 2 years up to 10 years. Step 2, patients with repeated tests in 2 years were categorized into 4 groups by the diseased duration of every 5 years. Step 3, the NMSS score changes in 6 years follow-up were determined, and the dosage of anti-PD drugs was compared to the NMSs severity changes. 676 patients completed the step 1 analysis, which showed a trend of NMSs worsening but not significant until the disease duration longer than 4–6 years. Furthermore, the severity did not change between repeated evaluations in 2 years in all patients. The progression became apparent after 6 years. Individual symptoms had different progression patterns and the increment of medications was independent to NMSs evolution. We demonstrated the NMSs severity progression in Taiwanese PD patients and the independence of the medications and NMSs progression.

show abstract

“…Dysarthria in Parkinson's disease (PD), which is a progressive neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra, is universal [1][2][3][4][5][6][7][8]. It was indicated that almost 89% of patients with PD developed dysarthria [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Lee Silverman Voice Treatment for dysarthria in patients with Parkinson’s disease: a systematic review and meta‐analysis

Yuan

Guo

Wei

et al. 2020

Euro J of Neurology

View full text Add to dashboard Cite

Approximately 89% of patients with Parkinson’s disease (PD) suffer from dysarthria. Lee Silverman Voice Treatment (LSVT), a behavioral therapy, aims to improve speech and voice functions. The objective was to assess the effectiveness of LSVT compared with other/no speech interventions for dysarthria in patients with PD. Electronic databases, including PubMed, Embase and the Cochrane Library, were searched. The publication date of all included studies was before 6 March 2020. Only randomized controlled trials (RCTs) that evaluated the LSVT intervention compared with other/no speech intervention were considered. The data obtained from the included studies were described and the mean differences were calculated. Eight RCTs were included in this meta‐analysis comparing LSVT with other/no speech interventions. In the comparison of LSVT versus no intervention, vocal intensity for sustained ‘Ah’ phonation, reading the ‘Rainbow passage’, monologue and describing a picture increased by 8.87, 4.34, 3.25 and 3.31 dB, respectively, after 1 month of therapy. Compared with the respiratory therapy group, the LSVT group also showed significant improvement in vocal intensity for sustained ‘Ah’ phonation, reading the ‘Rainbow passage’ and monologue immediately after treatment (13.39, 6.66 and 3.19 dB). Positive improvement still existed after 24 months. There was no difference in the therapeutic effect between face‐to‐face and online LSVT. The effectiveness of LSVT for dysarthria in patients with PD was verified in these trials. However, future RCTs with sufficient participants are essential to evaluate the effectiveness of LSVT for dysarthria.

show abstract

Progression of prodromal motor and non‐motor symptoms in the premotor phase study – 2‐year follow‐up data

Cited by 8 publications

References 11 publications

Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease

Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease

The severity progression of non-motor symptoms in Parkinson’s disease: a 6-year longitudinal study in Taiwanese patients

Lee Silverman Voice Treatment for dysarthria in patients with Parkinson’s disease: a systematic review and meta‐analysis

Contact Info

Product

Resources

About